ManNAc vs. Acenobel: GNE Myopathy Therapies Compared

For a rare, progressive condition like GNE myopathy, following the landscape of new therapies can be confusing, especially when navigating clinical trial results and international drug approvals. Both ManNAc and Acenobel are oral substrate replacement therapies—treatments designed to bypass the defective GNE enzyme to increase sialic acid production in your body ^[1]. While they share the same ultimate goal of restoring sialic acid levels, they use different chemical approaches and are at different stages of regulatory approval ^[2][3][4].

How They Work Differently

Acenobel (aceneuramic acid) is the direct end-product of the sialic acid pathway. By taking oral Acenobel, patients are directly supplementing sialic acid (also called N-acetylneuraminic acid) ^[5]. Because sialic acid is a “charged” molecule at normal body pH, its ability to passively pass through cellular membranes into muscle cells can be limited, often requiring specific transport mechanisms to enter the cells ^[4].

ManNAc (N-acetylmannosamine), on the other hand, is an oral precursor molecule—a building block that comes just before sialic acid in the body’s natural production process ^[3]. The key difference is that ManNAc is an uncharged (neutral) molecule ^[6]. Researchers believe this neutral state allows ManNAc to more easily penetrate muscle cell membranes through passive diffusion ^[6]. Once inside the cell, other cellular enzymes—working alongside any remaining functional parts of the GNE enzyme—convert ManNAc into the final sialic acid product ^[7].

Clinical Trial and Approval Status

The two therapies also differ significantly in their clinical development and availability:

• Acenobel (Aceneuramic acid): An extended-release formulation of aceneuramic acid was officially approved for the treatment of GNE myopathy in Japan in March 2024 based on local trial data ^[4]. However, it is important to note that a separate global Phase 3 clinical trial for a similar extended-release sialic acid product failed to show an overall improvement in muscle strength compared to a placebo, and it is currently not approved by the FDA or EMA for use in the US or Europe ^[2]. This discrepancy can be frustrating and confusing, but it reflects how different regulatory agencies interpret complex trial data in a rare disease where measuring slow changes in muscle strength is very difficult ^[8].
• ManNAc: ManNAc is currently still in the clinical trial phase and is not yet an approved treatment ^[9]. Phase 2 clinical trials have shown that oral ManNAc is safe over the long term, successfully increases sialic acid production (biochemical efficacy), and provides preliminary signs of clinical benefit—specifically, showing trends toward slowing down the loss of muscle strength ^[3][5]. Global Phase 3 studies have been planned to further evaluate its ability to prevent muscle atrophy and weakness over time ^[10].

At a Glance: ManNAc vs. Acenobel

Both therapies represent important steps forward in research for GNE myopathy, giving scientists and patients different avenues to potentially restore missing sialic acid. Navigating clinical trials or seeking access to overseas medications requires careful discussion with your neurology team to determine what options might be appropriate for you.